Retatrutide + MOTS-c Clinical Evidence Context Direct stack evidence No published human or animal trial has tested retatrutide + MOTS-c together
Drug Discovery Today, 22 (5), 796804
Patients with obesity may present with reduced CPT I levels leading to reduced levels of intracellular L-carnitine, which prevents them from using certain fatty acids for energy production, resulting in lipid accumulation in the cells especially in the adipose tissue and the liver [46,47]
Adds healthy dietary fiber
Staying hydrated and maintaining adequate nutrition during this period supports your body's adjustment to the medication
Greater caution is needed if you have severe, poorly controlled reflux, complications such as Barrett's oesophagus, difficulty swallowing, or severe gastroparesis